An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading
Tag Archives: MHC Class I
Immune Design files IPO for immuno-oncology CTL and T-helper platforms
Immune Design is the latest immuno-oncology company to file an Initial Public Offering to raise money to advance its platform technology and products. The company has 2 principal approaches to direct the immune system to fight cancer… Continue reading